bexagliflozin + glimepiride

**Bexagliflozin + glimepiride** is a fixed-dose combination composed of two distinct antihyperglycemic agents used for the management of type 2 diabetes mellitus. **Bexagliflozin** is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that lowers blood glucose by promoting renal glucose excretion[1][3][4][5]. **Glimepiride** is a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels on those cells[2]. This combination leverages complementary mechanisms: bexagliflozin increases urinary glucose elimination, while glimepiride boosts endogenous insulin production, collectively improving glycemic control. Clinical trial data support the efficacy and safety of concomitant use of bexagliflozin and glimepiride in adults with type 2 diabetes mellitus inadequately managed on other therapies[1][3].